Relationship between the frequency of hepatitis B virus infections and levels of serum adipokines in patients with hepatosteatosis and insulin resistance

Ayhan Balkan; Murat Taner Gulsen; Yasemin Balkan; Secil Kaya Cali

doi:10.5152/EurJTher.2017.20

Authors

Ayhan Balkan
Murat Taner Gulsen Gaziantep University; Gaziantep University; Gaziantep University
Yasemin Balkan Gaziantep University
Secil Kaya Cali Gaziantep University; Gaziantep University; Gaziantep University

DOI:

https://doi.org/10.5152/EurJTher.2017.20

Keywords:

Hepatosteatosis, insulin resistance, adipokine, hepatitis B virus

Abstract

Objective: Although the steatogenic effect of hepatitis B virus (HBV) has been established in several studies, it is not yet known whether it leads to hepatosteatosis in anti-HBc IgG-positive patients. This study aimed to investigate the relationship between the frequency of HBV and levels of serum adipokines in patients with hepatosteatosis and insulin resistance.

Methods: Eighty patients diagnosed with hepatosteatosis by ultrasonography, who were admitted to our polyclinic between July 2011 and June 2012 for various reasons, and who had insulin resistance were included. Homeostasis model assessment-insulin resistance of >2.7 was considered as insulin resistance, and these patients was investigated for anti-HBc IgG. The anti-HBc IgG level was analyzed by enzyme-linked immunosorbent assay. Levels of adiponectin, resistin, and leptin in serum samples were analyzed in anti-HBc IgG (+) and anti-HBc IgG (-) groups.

Results: Anti-HBc IgG was positive in 29 (36.2%) patients and negative in 51 (63.8%). While the level of leptin in the anti-HBc IgG (+) group was 31569.72 +/- 14027.64 ng/mL, it was 25410.73 +/- 10978.26 ng/mL in the anti-HBc IgG (-) group. The levels of leptin in the anti-HBc IgG (+) and anti-HBc IgG (-) groups were statistically significant (p=0.047). However, levels of adiponectin and resistin were not different between the groups.

Conclusion: These results suggest that anti-HBc IgG positivity is involved in the etiology of hepatosteatosis and insulin resistance as well.

Metrics

Metrics Loading ...

References

Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.

Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126: 137-45.

Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009; 24: 248-54.

McCullough AJ. The epidemiology and risk factors of NASH. In: Farrell GC, George J, dela M Hall P, McCullough AJ, editors. Fatty Liver Disease: NASH and Related Disorders. Malden, MA: Blackwell Publishing,2005; 23-37.

Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005; 43: 508-14.

Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.

Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 2005; 50: 171-80.

Van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008; 48: 449-57.

Nazal L, Riquelme A, Solís N, Pizarro M, Escalona A, Burotto M, et al. Hypoadiponectinemia and its association with liver fibrosis in morbidly obese patients. Obes Surg 2010; 20: 1400-7.

Savvidou S, Hytiroglou P, Orfanou-Koumerkeridou H, Panderis A, Frantzoulis P, Goulis J. Low serum adiponectin levels are predictive of advanced hepatic fibrosis in patients with NAFLD. J Clin Gastroenterol 2009; 43: 765-72.

Muse ED, Obici S, Bhanot S, Monia BP, McKay RA, Rajala MW, et al. Role of resistin in diet-induced hepatic insulin resistance. J Clin İnvest 2004; 114: 232-9.

Crespo J, Rivero M, Fábrega E, Cayón A, Amado JA, García-Unzeta MT, Pons-Romero F. Plasma leptin and TNF-alpha levels in chronic hepatitis C patients and their relationship to hepatic fibrosis. Dig Dis Sci 2002; 47: 1604-10.

Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.

Peng D, Han Y, Ding H, Wei L. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. J Gastroenterol Hepatol 2008; 23: 1082-8.

Chung HT, Lee JS, Lok AS. Prevention of posttransfusion hepatitis B and C by screening for antibody to hepatitis C virus and antibody to HBcAg. Hepatology 1993; 18: 1045-9.

Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997; 113: 1668-74.

Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 2010; 55: 560-78.

Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in Nonalcoholic Steatohepatitis: From Pathogenesis to Implications in Diagnosis and Therapy. Mediators Inflamm 2009; 2009: 831670.

Gordon A, McLean CA, Pedersen JS, Bailey MJ, Roberts SK. Hepatic steatosis in chronic hepatitis B and C: Predictors, distribution and effect on fibrosis. J Hepatol 2005; 43: 38-44.

Koziel MJ. Cytokines in viral hepatitis. Semin Liver Dis 1999; 19: 157-69.

Sennello JA, Fayad R, Morris AM, Eckel RH, Asilmaz E, Montez J, et al. Regulation of T cell-mediated hepatic inflammation by adiponectin and leptin. Endocrinology 2005; 146: 2157-64.

Stefanou N, Satra M, Papanikolaou V, Kalala F, Gatselis N, Germenis A, et al. Leptin receptor isoforms mRNA expression in peripheral blood mononuclear cells from patients with chronic viral hepatitis. Exp Biol Med 2006; 231: 1653-63.

Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001; 108: 1533-40.

Piche T, Gelsi E, Schneider SM, Hebuterne X, Giudicelli J, Ferrua B, et al. Fatigue is associated with high circulating leptin levels in chronic hepatitis C. Gut 2002; 51: 434-9.

Persico M, Iolascon A. Steatosis as a co-factor in chronic liver disease. World J Gastroenterol 2010; 16: 1171-6.

Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentration in normal-weight and obese humans. N Engl J Med 1996; 334: 292-5.

Wong VW, Wong GL, Yu J, Choi PC, Chan AW, Chan HY, et al. Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. Am J Gastroenterol 2010; 105: 132-8.

Hekimoğlu A. Role of Leptin on Physiopathologic Actions. Dicle Tıp Dergisi 2006; 33: 256-67.

Karaman A, Gürsoy Ş, Soyuer I, Karaman H, Torun ME, Yurci MA, et al. Effect of hepatic steatosis on virological response to nucleos(t)ide analogs therapy in patients with chronic hepatitis B. Turk J Med Sci 2013; 43: 70-4